Health of Health Care Stocks: Complementary Research on Enzon Pharmaceuticals, Durect Corporation, Vertex Pharmaceuticals, Advaxis, and Omnicare
24 Apr, 2015, 08:30 ET
NEW YORK, April 24, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN), Durect Corporation (NASDAQ: DRRX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Advaxis, Inc. (NASDAQ: ADXS), and Omnicare, Inc. (NYSE: OCR). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
ENZN Research Report: ( http://get.analystsreview.com/pdf/?c=Enzon%20Pharmaceuticals&d=24-Apr-2015&s=ENZN ),
DRRX Research Report: ( http://get.analystsreview.com/pdf/?c=Durect%20Corporation&d=24-Apr-2015&s=DRRX ),
VRTX Research Report: ( http://get.analystsreview.com/pdf/?c=Vertex%20Pharmaceuticals&d=24-Apr-2015&s=VRTX ),
ADXS Research Report: ( http://get.analystsreview.com/pdf/?c=Advaxis&d=24-Apr-2015&s=ADXS ),
OCR Research Report: ( http://get.analystsreview.com/pdf/?c=Omnicare&d=24-Apr-2015&s=OCR ).
Analyst Update: Results Update, Upcoming Financial Events and Conference Participation
Reviewed by: Rohit Tuli, CFA®
U.S. stocks continued to surge to record highs on Thursday as the Nasdaq Composite closed at its highest level ever, supported by better than expected corporate earnings. The Nasdaq Composite gained 0.41%, or 20.89 points to close at an all-time record high of 5056.06. The S&P 500 advanced 0.24%, or 4.97 points to 2112.93, and the Dow Jones Industrial Average closed the session at 18,058.69, up 0.11% or 20.42 points. European stocks mostly closed lower on Thursday as investors remained vigil on Greece's debt turmoil and cash crunch situation. Germany's DAX 30 and France's CAC 40 dropped 1.21% and 0.62%, respectively, while London's FTSE 100 gained modestly by 0.3% on Thursday. Meanwhile, Asian stock markets mostly advanced on Thursday as the Shanghai Composite and Japan's Nikkei both closed higher.
According to an article on Insider Monkey published on April 1, 2015, Enzon Pharmaceuticals Inc., the $46.39 million Company, is currently waiting to be acquired by another concern as it has put brakes on the clinical research and is instead banking on royalty revenues.
On March 30, 2015, DURECT Corporation announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program, reported on Yahoo finance. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE) that may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steato hepatitis (NASH).
Vertex Pharmaceuticals stock rose 5.3% to close at $132.2 on April 21, 2015 after analysts at Bernstein urged a buyout bid from fellow drugmaker Gilead Sciences, Inc. Bernstein analyst noted that Gilead has both the cash as well as the need for externally acquired drug revenue. The analyst predicted the "inevitable simultaneous decline" of the Company's two key drug franchises for treating HIV and Hepatitis C.
On April 21, 2015, Advaxis Inc. announced the data of one clinical and two preclinical studies highlighting the survival outcomes and anti-tumor effects of its proprietary Lm-LLO cancer immunotherapy technology at the American Association for Cancer Research Annual Meeting 2015.
On March 24, 2015, the US Supreme Court said that securities issuers can't be sued over expressions of pure opinion in a securities registration statement, with an important caveat: Unless, the court said, they leave out material facts that would lead an investor to conclude the opinion was false, reported Forbes.com.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Share this article